BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 31644584)

  • 1. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
    Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
    PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetic landscape of histologically transformed marginal zone lymphomas.
    Li A; Yi H; Deng S; Ruan M; Xu P; Huo Y; Lu H; Shen X; Ouyang B; Cai M; Xu H; Wang Z; Zhang L; Zhu L; Peng Q; Gu Y; Xie J; Wang Y; Dong L; Liu Z; Wang C
    Cancer; 2024 Apr; 130(8):1246-1256. PubMed ID: 37941429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters.
    Filho EHCN; Zancheta SB; de Barros Silva PG; Rodríguez Burbano RM; Rabenhorst SHB
    J Clin Exp Hematop; 2023; 63(3):164-172. PubMed ID: 37766562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.
    Gill KZ; Iwamoto F; Allen A; Hoehn D; Murty VV; Alobeid B; Bhagat G
    PLoS One; 2014; 9(12):e114398. PubMed ID: 25479599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
    Zhang LF; Zhang Y; Shui RH; Lu HF; Jiang WH; Cai X; Li XQ; Yu BH
    Diagn Pathol; 2024 Apr; 19(1):60. PubMed ID: 38627702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.
    Yang M; Niu X; Yang X; Sun Y; Su W; Zhang J; Wu Q; Wang Y; Zhang Q; Ji H
    Exp Biol Med (Maywood); 2023 Sep; 248(17):1469-1478. PubMed ID: 36847415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning.
    Tavolara TE; Niazi MKK; Feldman AL; Jaye DL; Flowers C; Cooper LAD; Gurcan MN
    Diagn Pathol; 2024 Jan; 19(1):17. PubMed ID: 38243330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
    Cooper A; Tumuluru S; Kissick K; Venkataraman G; Song JY; Lytle A; Duns G; Yu J; Kotlov N; Bagaev A; Hodkinson B; Srinivasan S; Smith SM; Scott DW; Steidl C; Godfrey JK; Kline J
    J Clin Oncol; 2024 Feb; 42(4):467-480. PubMed ID: 38079587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Characteristics and Correlation with Prognosis of DLBCL with Bone Marrow Involvement and Chromosomal Abnormalities].
    Li XL; Guan T; Zhao ZQ; Liu XL; Wang H; Su LP; Wang LY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1366-1371. PubMed ID: 37846686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse Large B-Cell Lymphoma with Aberrant Coexpression of CD5 and CD8 T-Cell Markers.
    Fan J; Thanedar S; Ovechko V; Jana B
    Case Rep Oncol; 2024; 17(1):517-523. PubMed ID: 38549625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
    Caracciolo D; Polerà N; Belmonte B; Conforti F; Signorelli S; Gulino A; Staropoli N; Tuccillo FM; Bonelli P; Juli G; Grillone K; Ascrizzi S; Cirillo M; Migale L; Ballerini A; Pelizon C; Di Martino MT; Tagliaferri P; Riillo C; Tassone P
    Br J Haematol; 2024 Feb; 204(2):555-560. PubMed ID: 37963444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.
    Miyazaki K; Asano N; Yamada T; Miyawaki K; Sakai R; Igarashi T; Nishikori M; Ohata K; Sunami K; Yoshida I; Yamamoto G; Takahashi N; Okamoto M; Yano H; Nishimura Y; Tamaru S; Nishikawa M; Izutsu K; Kinoshita T; Suzumiya J; Ohshima K; Kato K; Katayama N; Yamaguchi M
    Haematologica; 2020 Sep; 105(9):2308-2315. PubMed ID: 33054055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD5
    Lu TX; Wu S; Zhou XY; Zhang Y; Hong TT; Cai DY; Hua HY; Qi XW; Wu XH
    Exp Mol Pathol; 2020 Feb; 112():104326. PubMed ID: 31706988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De Novo CD5
    Xu Y; Sun W; Li F
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD5+ diffuse large B-cell lymphoma: a narrative review.
    Durani U; Ansell SM
    Leuk Lymphoma; 2021 Dec; 62(13):3078-3086. PubMed ID: 34284686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
    Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F
    J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.
    Ma D; Ma Y; Ma Y; Liu J; Gu Y; Liu N; Xiang C; Liu H; Sang W
    Front Oncol; 2022; 12():941347. PubMed ID: 36081566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Hwang J; Suh C; Kim K; Kim H; Kim AI; Craig JW; Chen KX; Roberson J; Guenette JP; Huang RY
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion. Close resemblance of its clinicopathological features to intravascular large B-cell lymphoma, but not to DLBCL-not otherwise specified.
    Itami H; Nakamine H; Kubo M; Ogawa K; Tani R; Nakamura S; Takeda M; Nitta Y; Uchiyama T; Fujii T; Hatakeyama K; Ohbayashi C
    J Clin Exp Hematop; 2021 Sep; 61(3):152-161. PubMed ID: 34193753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications.
    Papageorgiou SG; Thomopoulos TP; Katagas I; Bouchla A; Pappa V
    Ther Adv Hematol; 2021; 12():20406207211013987. PubMed ID: 34104369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.